Molecular Oncology
Volume 2, Issue 4 , Pages 296-316 , December 2008

Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene

  • Jirina Bartkova

      Affiliations

    • Institute Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark
    • These authors contributed equally to the work.
    • ,
  • Johanna Tommiska

      Affiliations

    • Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH), FI-00029 Helsinki, Finland
    • These authors contributed equally to the work.
    • ,
  • Lenka Oplustilova

      Affiliations

    • Institute Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark
    • Laboratory of Genome Integrity, Palacky University, Olomouc, Czech Republic;
    • These authors contributed equally to the work.
    • ,
  • Kirsimari Aaltonen

      Affiliations

    • Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH), FI-00029 Helsinki, Finland
    • Department of Oncology, HUCH, Helsinki, Finland
    • ,
  • Anitta Tamminen

      Affiliations

    • Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH), FI-00029 Helsinki, Finland
    • ,
  • Tuomas Heikkinen

      Affiliations

    • Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH), FI-00029 Helsinki, Finland
    • ,
  • Martin Mistrik

      Affiliations

    • Institute Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark
    • Laboratory of Genome Integrity, Palacky University, Olomouc, Czech Republic;
    • ,
  • Kristiina Aittomäki

      Affiliations

    • Department of Clinical Genetics, HUCH, Helsinki, Finland
    • ,
  • Carl Blomqvist

      Affiliations

    • Department of Oncology, HUCH, Helsinki, Finland
    • Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Päivi Heikkilä

      Affiliations

    • Department of Pathology, HUCH, Helsinki, Finland
    • ,
  • Jiri Lukas

      Affiliations

    • Institute Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark
    • ,
  • Heli Nevanlinna

      Affiliations

    • Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH), FI-00029 Helsinki, Finland
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jiri Bartek

      Affiliations

    • Institute Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark
    • Laboratory of Genome Integrity, Palacky University, Olomouc, Czech Republic;
    • Corresponding Author InformationCorresponding author. Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Tel.: +45 35 25 73 57; fax: +45 35 25 77 21.

Received 17 August 2008 ,Revised 11 September 2008 ,Accepted 14 September 2008.

References 

  1. Aagaard L, Lukas J, Bartkova J, Kjerulff AA, Strauss M, Bartek J. Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer. 1995;61:115–120
  2. Adams KE, Medhurst AL, Dart DA, Lakin ND. Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex. Oncogene. 2006;25:3894–3904
  3. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25:5906–5911
  4. Angele S, Treilleux I, Bremond A, Taniere P, Hall J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology. 2003;43:347–353
  5. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991;6:1699–1703
  6. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr. Opin. Cell Biol. 2007;19:238–245
  7. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26:7773–7779
  8. Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nature Rev. Mol. Cell. Biol. 2004;5:792–804
  9. Bartkova J, Horejsi Z, Koed K, Guldberg P, Krämer A, Sehested M, et al DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870
  10. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, Lukas J, et al. ATM activation in normal human tissues and testicular cancer. Cell Cycle. 2005;4:838–845
  11. Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De ME, Skakkebaek NE, et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene. 2007;26:7414–7422
  12. Bekker-Jensen S, Lukas C, Melander F, Bartek J, Lukas J. Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are coordinated by Mdc1/NFBD1. J. Cell Biol. 2005;170:201–211
  13. Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol. 2006;173:195–206
  14. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917
  15. Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J. 2003;22:6610–6620
  16. Celis JE, Gromova I, Cabezón T, Gromov P, Shen P, Timmermans-Wielenga V, et al. Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: Relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Molecular Oncology. 2007;1:321–349
  17. Cerosaletti K, Wright J, Concannon P. Active role for nibrin in the kinetics of atm activation. Mol. Cell. Biol. 2006;26:1691–1699
  18. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008;9:616–617
  19. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–244
  20. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, et al A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 2007;39:352–358
  21. Di Micco R, Fumagalli M, Cicalese A, Piccini S, Gasparini P, Luise C, et al Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638–642
  22. DiTullio RA, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nature Cell Biol. 2002;4:998–1002
  23. Ebi H, Matsuo K, Sugito N, Suzuki M, Osada H, Tajima K, et al. Novel NBS1 heterozygous germ line mutation causing MRE11-binding domain loss predisposes to common types of cancer. Cancer Res. 2007;67:11158–11165
  24. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7:93–100
  25. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Relationship of patients’ age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7:465–469
  26. Eerola H, Heinonen M, Heikkila P, Kilpivaara O, Tamminen A, Aittomaki K, et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2008;10:R17
  27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  28. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, et al A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316–319
  29. Fagerholm R. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. In:  Hofstetter B,  Tommiska J,  Aaltonen K,  Vrtel R,  Syrjäkoski K,  Kallioniemi A,  Kilpivaara O,  Mannermaa A,  Kosma VM editor. Nat. Genet. 40:2008;p. 8444–8845
  30. Falck J, Petrini JHJ, Williams BR, Lukas J, Bartek J. The DNA damage-dependent intra-S-phase checkpoint is regulated by parallel pathways. Nat. Genet. 2002;30:290–294
  31. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature. 2005;434:605–611
  32. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921
  33. Ganguly A. An update on conformation sensitive gel electrophoresis. Hum. Mutat. 2002;19:334–342
  34. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep. 2002;3:248–254
  35. Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, Viel A, et al Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene. 2004;23:2640–2647
  36. Goldberg M, Stucki M, Falck J, D'Amours D, Rahman D, Pappin D, et al. The MDC1 protein is required for the intra-S-phase DNA damage checkpoint. Nature. 2003;421:952–956
  37. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–913
  38. Górski B, Debniak T, Masojć B, Mierzejewski M, Medrek K, Cybulski C, et al Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int. J. Cancer. 2003;106:379–381
  39. Halazonetis T, Gorgoulis V, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–1355
  40. Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundán T, et al RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006;27:1593–1599
  41. Horejsi Z, Falck J, Bakkenist C, Kastan M, Lukas J, Bartek J. Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation. Oncogene. 2004;23:3122–3127
  42. Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1complex. Cancer Epidemiol Biomarkers Prev. 2007;16:2024–2032
  43. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GCM, Lukas J, et al. ATM- and cell cycle-dependent ATR regulation in response to DNA double-strand breaks. Nat. Cell Biol. 2006;8:37–45
  44. Krämer A, Mailand N, Lukas C, Syljuåsen RG, Wilkinson CJ, Nigg EA, et al. Centrosome-associated Chk1 prevents premature actibation of cyclin-D-Cdk1 kinase. Nature Cell Biol. 2004;6:884–891
  45. Kastan M, Bartek J. Cell cycle checkpoints and cancer. Nature. 2004;432:316–323
  46. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J, et al Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int. J. Cancer. 2005;113:575–580
  47. Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double strand breaks. Oncogene. 2007;26:7749–7758
  48. Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, et al Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women < or =55 years. Carcinogenesis. 2006;27:2209–2216
  49. Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation, yet correlates with tissue biology. Cancer Res. 2001;61:4990–4993
  50. Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatio-temporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat. Cell Biol. 2003;5:255–260
  51. Lukas C, Melander F, Stucki M, Falck J, Bekker-Jensen S, Goldberg M, et al. Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J. 2004;23:2674–2683
  52. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: Signalling pathways and their organization in space and time. DNA Repair. 2004;3:997–1007
  53. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006;25:5912–5919
  54. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, et al Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7:193–204
  55. Rupnik A, Grenon M, Lowndes N. The MRN complex. Curr. Biol. 2008;18:R455–R457
  56. Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J. Involvement of Myc activity in a G1/S-promoting mechanism parallel to the pRb/E2F pathway. Mol. Cell. Biol. 2000;20:3497–3509
  57. Sartori A, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, et al. Human CtIP promotes DNA end resection. Nature. 2007;450:509–514
  58. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 2000;151:1381–1390
  59. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, et al Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 2006;38:1239–1241
  60. Seemanová E, Jarolim P, Seeman P, Varon R, Digweed M, Swift M, et al. Cancer risk of heterozygotes with the NBN founder mutation. J. Natl. Cancer Inst. 2007;24:1875–1880
  61. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157–170
  62. Shiloh Y. The ATM-mediated DNA damage response: taking shape. Trends Biochem. Sci. 2006;31:402–410
  63. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NGJ, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell. 1999;99:577–587
  64. Soderlund K, Stal O, Skoog L, Rutqvist LE, Nordenskjold B, Stenmark Askmalm M. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:50–58
  65. Stracker TH, Theunissen JW, Morales M, Petrini JH. The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. DNA Repair. 2004;3:845–854
  66. Stracker TH, Morales M, Couto SS, Hussein H, Petrini JH. The carboxy terminus of NBS1 is required for induction of apoptosis by the MRE11 complex. Nature. 2007;447:218–221
  67. Sørensen CS, Syljuåsen RG, Falck J, Schroeder T, Rönnstrand L, Zhou B-B, et al. Chk1 regulates the S-phase checkpoint by coupling the physiological turnover and ionising radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell. 2003;3:247–258
  68. Sørensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 2005;7:195–201
  69. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell Biol. 2005;25:3553–3562
  70. Syrjäkoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, et al Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J. Natl. Cancer Inst. 2000;92:1529–1531
  71. Tassan JP, Schultz SJ, Bartek J, Nigg AE. Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J. Cell Biol. 1994;127:467–478
  72. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, et al Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 2005;11:5098–5103
  73. Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, et al Evaluation of RAD50 in familial breast cancer predisposition. Int. J. Cancer. 2006;118:2911–2916
  74. Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, et al The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27:2501–2506
  75. Trenz K, Smith E, Smith S, Costanzo V. ATM and ATR promote Mre11 dependent restart of collapsed replication forks and prevent accumulation of DNA breaks. EMBO J. 2006;25:1764–1774
  76. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 2003;22:5612–5621
  77. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br. J. Cancer. 2001;84:704–708
  78. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 2002;71:432–438
  79. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, et al Nibrin, a novel DNA double strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 1998;93:467–476
  80. Vehmanen P, Friedman L, Eerola H, McClure M, Ward B, Sarantaus L, et al Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: strong evidence for additional susceptibility genes. Hum. Mol. Genet. 1997;6:2309–2315
  81. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of human p53: New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 1992;151:237–244
  82. Walsh T, King MC. Ten genes for inherited breast cancer. Cell. 2007;11:103–105
  83. Wen Q, Scorah J, Phear G, Rodgers G, Rodgers S, Meuth M. A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol. Biol. Cell. 2008;19:1693–1705
  84. Zhou BB, Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat. Rev. Cancer. 2004;4:216–225

PII: S1574-7891(08)00121-X

doi: 10.1016/j.molonc.2008.09.007

Molecular Oncology
Volume 2, Issue 4 , Pages 296-316 , December 2008

Article Tools

* Image Usage & Resolution